SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is), also known as a glifozins, constitute a class of medication that was initially approved as an antidiabetic agent because the mechanism of action consisted of lowering blood glucose levels by promoting excretion of glucose through the kidneys via renal tubules.1,2 As the medication was further studied, it was found to have positive cardioprotective effects in multiple recent large-scale randomized clinical trials (RCTs), not limited to the patients with type 2 diabetes.